134
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Non-alcoholic fatty liver disease: a brief review

Pages 56-59 | Published online: 08 Jul 2009

References

  • Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–8.
  • Diehl AM. Nonalcoholic steatohepatitis. Sem Liv Dis 1999; 19: 221–9.
  • McCullough AJ. Update on non-alcoholic fatty liver disease. J Clin Gastroenterol 2002;34:155–62.
  • AGA Clinical Practice Committee, AASLD Practice Guidelines Committee. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123:1702–4.
  • AGA Clinical Practice Committee, AASLD Practice Guidelines Committee. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705–25.
  • Goodman JI. Hepatomegaly and diabetes mellitus. Ann Intern Med 1953;39:1077.
  • Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103–9.
  • Batman PA, Scheuer PJ. Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology 1985;9:237.
  • Van Hoek B. Non-alcohol steatohepatitis: state-of-the-art. Br Med J 2001;16 Suppl:28(IX)–28(X).
  • Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR 1998;171:659–64.
  • Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Sem Liver Dis 2001;21:71–80.
  • Raptopoulos V, Karellas A, Bernstein J, Reale FR, Constantinou C, Zawacki JK. Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses. Am J Roentgenol 1991;157:721.
  • Levenson H, Greensite F, Hoefs J, Friloux L, Applegate G, Silva E, et al. Fatty infiltration of the liver: quantitation with phase-contrast MR imaging at 1.5 T vs biopsy. Am J Roentgenol 1991; 156:307–12.
  • Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137–45.
  • Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis. Hepatology 1990;11:74–80.
  • Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999;30:1356–62.
  • Latry P, Bioulac–Sage P, Echinard E, Gin H, Boussarie L, Grimaud JA, et al. Peri-sinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients. Hum Pathol 1987;18:775.
  • Lee RG. Nonalcoholic steatohepatitis. Human Pathol 1989;20: 594–8.
  • Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.
  • Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513–7.
  • George DK, Goldwurm S, MacDonald, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311–8.
  • Ferranini E. Insulin resistance, iron and the liver. Lancet 2000; 355:2181–2.
  • Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–9.
  • Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689–92.
  • Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinico-pathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172–9.
  • Kim WR, Poterucha JJ, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802–5.
  • Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467–74.
  • Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of non-alcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714–9.
  • Maher JJ. Alcoholic liver disease. In: Feldman M, Scharschmidt BF, Sleisinger MH, editors. Gastrointestinal and liver disease. 6th ed. Philadelphia: WB Saunders Company; 1998. p. 1199–214.
  • Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis [letter]. Gastroenterology 1995; 108: 1607.
  • Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in nonalcoholic steatohepatitis. Pathol Inst 2001;51:127–31.
  • Klein S. Total parenteral nutrition and the liver. In: Schiff L, Schiff ER, editors. Diseases of the liver. 7th ed. Philadelphia: Lippincott; 1993. p. 1505–16.
  • Tankurt E, Biberoglu S, Ellidokuz, Hekimsoy Z, Akpinar H, Comlekci A, et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999;31:963.
  • Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107: 450–5.
  • Clain DJ, Lefkowitch JH. Fatty liver in morbid obesity. Gastroenterol Clin North Am 1987;16:239–52.
  • Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117–23.
  • Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. Med Clin North Am 1996;80:1147–66.
  • Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106–10.
  • Day CP, James OF. Steatohepatitis: a tale of two ‘hits’? [editorial]. Gastroenterology 1998;114:842–5.
  • Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3–10.
  • Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis leads to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200.
  • James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29: 495–501.
  • Tilg H, Diehl AM. Mechanisms of disease: cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467–76.
  • Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131–8.
  • Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 1997;94:2557–62.
  • Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292–8.
  • Selzner M, Clavien PA. Failure of regeneration of the steatotic liver: disruption at two different levels in the regeneration pathway. Hepatology 2000;31:35–42.
  • Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000;46: 540–5.
  • Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99: 1408–13.
  • Berkowitz D. Metabolic changes associated with obesity before and after weight reduction. JAMA 1964;187:103–10.
  • Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Med 2000;6:998–1003.
  • Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893–4.
  • Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:519–25.
  • Krentz AJ, Baily CJ, Melander A. Thiazolidinediones for type 2 diabetes. Br Med J 2000;321: 252–3.
  • Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol induced steatohepatitis. Hepatology 1996;23:1464–7.
  • Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000;136:734–8.
  • Abdelmalek MF, Angulo P, Jorgenson RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2001;96: 2711–7.
  • Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000;50:722–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.